Grail Inc. shares fell sharply in pre-market activity, dropping 11.6% to $127 after the company released third-quarter 2026 results that failed to meet Wall Street revenue expectations. The company reported third-quarter revenue of $37.5 million, a 17% shortfall compared with the analyst consensus of $45.3 million.
Volume for the Galleri multi-cancer early detection test did improve, increasing 24% to more than 56,000 tests. However, a shift toward promotional pricing pulled the average selling price down to about $660 and cut non-GAAP adjusted gross margin to 42% from 55% in the prior period.
On the profitability side, Grail registered a net loss of $103.6 million for the quarter. Non-GAAP adjusted EBITDA was negative $92.6 million, illustrating a widening operating deficit despite higher test volumes. Management highlighted a regulatory milestone - an FDA Advisory Committee voted in favor of approval of the Galleri test - but investors concentrated on the deteriorating near-term financial metrics.
Analysts reacted to the results by trimming price targets and adjusting expectations for near-term revenue. TD Cowen reduced its price target to $175 from $180. Baird kept an Outperform rating but lowered its target to $150 from $155. Both firms' moves were cited as reflecting reduced revenue expectations after the quarterly shortfall.
Insider activity also added to selling pressure: company insiders sold 129,944 shares worth approximately $14.8 million over the last three months, a fact noted in investor commentary as an additional overhang on the stock.
Macro conditions provided little cushion for high-growth, unprofitable healthcare names. The NASDAQ slipped 0.8%, while the S&P 500 was essentially flat, up 0.1%. Broader healthcare indices and peers in the multi-cancer early detection space did not experience similar moves, indicating the market response was focused on Grail specifically rather than a sector-wide rotation.
Taking the results together, the market reaction reflects several factors: a material revenue miss, margin erosion tied to promotional pricing, a larger reported net loss and a widening negative adjusted EBITDA. These elements, combined with analyst price-target cuts and insider sales, drove the pre-market selloff in the company’s shares.
There were some points management emphasized as potential mitigants. Grail raised its full-year Galleri sales revenue growth guidance to a range of 17% to 21%, and the company closed the quarter with $788.7 million in cash. Management stated that the cash position provides runway into 2029. While those items may constrain additional downside, they were insufficient to offset investor disappointment with the top-line miss in the reported quarter.
Key financials and operational highlights
- Third-quarter revenue: $37.5 million (consensus $45.3 million)
- Galleri test volume: up 24% to more than 56,000
- Average selling price: roughly $660, with adjusted gross margin falling to 42% from 55%
- Net loss: $103.6 million; non-GAAP adjusted EBITDA: negative $92.6 million
- Cash at quarter-end: $788.7 million, with management stating runway into 2029
Market and analyst reaction
- Pre-market share decline: 11.6% to $127
- TD Cowen price target: cut to $175 from $180
- Baird: maintained Outperform, lowered target to $150 from $155
- Insider sales over last three months: 129,944 shares worth about $14.8 million